Status:
RECRUITING
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
Lead Sponsor:
Closed Loop Medicine
Conditions:
Obesity & Overweight
Eligibility:
All Genders
18+ years
Brief Summary
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucago...
Detailed Description
Researchers at Amarillo Premier Research, working with Closed Loop Medicine Ltd (CLM), want to improve how excess weight and obesity are managed. There is a need for tools that support more consistent...
Eligibility Criteria
Inclusion
- Participants must be 18 years or older.
- Participants must have a diagnosis of either obesity or overweight.
- Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).
- Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.
- Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.
Exclusion
- Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.
- Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.
Key Trial Info
Start Date :
September 23 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07216651
Start Date
September 23 2025
End Date
January 31 2026
Last Update
October 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amarillo Premier Research (an Objective Health Partnership)
Amarillo, Texas, United States, 37067